Litcius/Paper detail

Real-Time Whole Genome Sequencing to Guide Patient-Tailored Therapy of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Luke B. Snell, Adela Alcolea-Medina, Themoula Charalampous, Christopher Alder, Tom Williams, Flavia Flaviani, Rahul Batra, Prijay Bakrania, Rajeni Thangarajah, Stuart J. D. Neil, Claire van Nispen tot Pannerden, Alina Botgros, Emma Aarons, Sam Douthwaite, Jonathan D. Edgeworth, Gaia Nebbia

2022Clinical Infectious Diseases10 citationsDOIOpen Access PDF

Abstract

The management of coronavirus disease 2019 has become more complex due to the expansion of available therapies. The presence of severe acute respiratory syndrome coronavirus 2 variants and mutations further complicates treatment due to their differing susceptibilities to therapies. Here we outline the use of real-time whole genome sequencing to detect persistent infection, evaluate for mutations confering resistance to treatments, and guide treatment decisions.

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)GenomeCoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DNA sequencingWhole genome sequencing2019-20 coronavirus outbreakMutationVirologyIntensive care medicineDiseaseBioinformaticsInternal medicineGeneInfectious disease (medical specialty)GeneticsBiologyOutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesPARP inhibition in cancer therapy